Navigation Links
Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
Date:10/15/2008

OLDSMAR, Fla., Oct. 15 /PRNewswire-FirstCall/ -- Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL) (the "Company"), one of the world's largest and most established family cord blood banks, today announced results for the third quarter and nine months ended August 31, 2008.

Consolidated revenues for the third quarter were approximately $4.5 million compared to approximately $4.6 million for the third quarter of 2007. The Company reported a net loss in the third quarter 2008 of approximately ($189,000), or ($0.02) per basic common share, compared to a net loss of approximately ($1,148,000), or ($0.10) per basic common share, in the third quarter of 2007. The decrease in the net loss in the third quarter of fiscal 2008 is primarily the result of a 24% decrease in marketing, general and administrative expenses. In addition, research and development expenses were approximately $68,000 in the third quarter of 2008, a decrease of approximately 58% in comparison to the same period in 2007. Research and development expenses in 2008 represented expenses related to the development of the Company's new C'elle(R) menstrual stem cell technology.

The Company recognized approximately $293,000 in licensee income for the third quarter of fiscal 2008, compared to approximately $226,000 for the 2007 period. On February 20, 2008, the Company entered into a definitive License and Royalty Agreement with Cryo-Cell de Venezuela to market its U-Cord program in Venezuela and to collect and ship the specimens to the Company's facility in Oldsmar, FL. The non-refundable up-front license fee of $200,000 is expected to be paid by Cryo-Cell de Venezuela in installments. The Company received the first installment payment of $100,000 during the first quarter of fiscal 2008. The agreement was amended on August 29, 2008. The amendment to the agreement acknowledges that the first installment payment is non-refundable and the Company recognized the $100,000 payment during the
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
3. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
4. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
5. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
6. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
7. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
8. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
9. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
10. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
11. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., Nov. 27 Cromoz Inc., located in ...e carbon nanotube-based cancer drug delivery syste...notubes, which have functional groups on the walls...s developed in partnership with the Indian Institu...s serves as a drug delivery vehicle with the abili...
(Date:11/26/2009)... new generation of ultrasmall transistors and more...led semiconducting nanowires are closer to reality...ue University and the University of California at ...to create nanowires with layers of different mater... which is a critical requirement for making effici...
(Date:11/25/2009)...ssador to Speak at Economic Club of Canada , ...er 25, 2009 -- Ambassador to Speak at Economic Clu...bassador for International Investment, and Chairma...a biography of David Appia go to www.investinfran...e to meet with press to discuss recent pro-busines...
(Date:11/25/2009)..., Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd...ines, announced today that it executed,a joint ven...Vaccine,Technology Co., Ltd. (Sinovac Dalian). The...ize human-use vaccines. Sinovac will contribute it...rcializing world-class vaccines; the,other party w...
Breaking Biology Technology:North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3French Ambassador for International Investment to Visit Toronto December 11 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3
...rta and the National Research Council,s National I... an approach that is leading to improved performan...lls). The development of inexpensive, mass-produce...st for many of the world,s scientists and engineer...ra-high purity silicon and other materials normall...
...ates Anti-Tumor Activity Across Doses and Endpoint... Patients - , , - Data To Be Presented at ASCO,s ...vation to Host Conference Call and Webcast Present...tern Time - , , SAN FRANCISCO, Feb. 25 Medivati...sentation of new efficacy and safety data from an ...
...harmaceuticals Inc.,(Nasdaq: TRBN ) today announ...cent, or 25 employees, and a corporate restructuri...apital markets and the global economy, Trubion,is ...lign its current,resources with its strongest near...for long-term sustainability and success. , Fo...
Other Biology Technology:University of Alberta and NINT researchers make solar energy breakthrough 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 5Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring 2Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring 3Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring 4
(Date:11/30/2009)... December 2009 print issue of The FASEB Journal ...r their fertility that women have had since the 19...where androgenic hormones work in the testis to co...This opens a promising avenue for the development ...ope to those who cannot have children because of l...
(Date:11/30/2009)...dioactive gas that is produced by the radioactive ...cay and is found in trace amounts naturally in nea...uilding materials, plants, animals, and the human ... amount of radiation that would be emitted by rado...he units are picocuries per liter (pCi/L). The Ame...
(Date:11/26/2009)...ed deer have been caught in the hunters, sights fo...than decorative. They are lethal weapons that stag...The University of York, UK, has been intrigued by ...century and has become fascinated by the mechanica...laboration with Tomas Landete-Castillejos at the U...
Breaking Biology News(10 mins):Health Physics Society recommends considering action for indoor radon below current guidelines 2Tough yet stiff deer antler is materials scientist's dream 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 1 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 3 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 4 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 5 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 6 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 7 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 8 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 9Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 1Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 1Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 3Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 4
... written book describes hundreds of well-known and...rporate leaders, and literary greats who used or a...esidents, seven popes, Sir William Osler, J.D. Roc...re among those famous people who were known to hav...ngly is the evidence of Charles Darwins use of hom...
...o the way in which parasites interact with each ot...e likely to break out. , A group of scientists i...r of infectious parasites in rabbits. The findings...ssfully when infectious cyclical diseases in human...niversitys School of Biosciences, University of St...
...ses, such as when to multiply, are often regulated... of interactions between proteins. North Carolina ...y in which a specific protein-protein interaction ... off, leading to uncontrolled cell proliferation ...ished in the December 2007 edition of the Cell Pre...
Other Biology News:The surprising story of Charles Darwin and his homeopathic doctor 2The surprising story of Charles Darwin and his homeopathic doctor 3Can interacting pathogens explain disease patterns? 2Why the switch stays on 2Why the switch stays on 3
X-gal from BioPioneer
Angiogenesis Tube formation Assay Kit from Upstate
Monkey IL-6 ELISPOT Kit, With white/opague microtiter plates from Cell Sciences
Histone Deacetylase Radiometric (3H) Assay Kit from Upstate
Biology Products: